A serum-mediated mechanism for concomitant resistance shared by immunogenic and non-immunogenic murine tumours

British Journal of Cancer

Volumn 74, Issue 2, 1996, Pages 178-186

  Franco, M ^a   Bustuoabad, O D ^a   Di Gianni, P D ^a   Goldman, A ^a   Pasqualini, C D ^a   Ruggiero, R A ^a,b  

^a INST DE INVEST HEMATOLOGICAS   (Argentina)

^b ACADEMIA NACIONAL DE MEDICINA   (Argentina)

Author keywords

Anti tumour factor; Concomitant immunity; Concomitant resistance

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOGENICITY; MALE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; SERUM FACTOR; T LYMPHOCYTE; THYMUS; TUMOR RESISTANCE;

EID: 0030016125     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.335     Document Type: Article

References (39)

1. AKPORIAYE ET, KUDALORE M, STEVENSON AP, KRAEMER PM AND STEWART CC. (1988). Isolation and reactivity of host effectors associated with the manifestation of concomitant tumor immunity. Cancer Res., 48, 1153-1158.
2. ATTIA MA AND WEISS DW. (1966). Immunology of spontaneous mammary carcinomas in mice. V. Acquired tumor resistance and enhancement in strain A mice infected with mammary tumor virus. Cancer Res., 26, 1787-1800.
3. BELEHRADEK J, BARSKI G AND THONIER M. (1972). Evolution of cell-mediated antitumor immunity in mice bearing a syngeneic chemically induced tumor. Influence of tumor growth, surgical removal and treatment with irradiated tumor cells. Int. J. Cancer, 9, 461-469.
4. BERENDT MJ, NORTH RJ AND KIRSTEIN DP. (1978). The immunological basis of endotoxin-induced tumor regression. J. Exp. Med., 148, 1560-1569.
5. BEUTLER B AND CERAMI A. (1986). Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature, 320, 584-588.
6. BONFIL RD, RUGGIERO RA, BUSTUOABAD OD, MEISS RP AND PASQUALINI CD. (1988). Role of concomitant resistance in the development of murine lung metastases. Int. J. Cancer, 41, 415-422.
7. BONFIL RD, SORASIO MC, LUCERO GRITTI MF, BUSTUOABAD OD, MEISS RP, KORDON E, LANARI C AND PASQUALINI CD. (1989). Caracterización del adenocarcinoma mamario murino C7HI, un nuevo modelo para el estudio de las metástasis. Medicina (Buenos Aires) 49, 479.
8. 51Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology, 14, 181-196.
9. CHANDRADASA KD. (1973). The development and specific suppression of concomitant immunity in two syngeneic tumour-host systems. Int. J. Cancer, 11, 648-662.
10. DECKERS PJ, DAVIS RC, PARKER GA AND MANNICK JA. (1973). The effect of tumor size on concomitant tumor immunity. Cancer Res., 33, 33-39.
11. DE WYS WD. (1972). Studies correlating the growth rate of a tumor and its metastases and providing evidence for tumor-related systemic growth-retarding factors. Cancer Res., 32, 374-379.
12. FINLAY-JONES JJ, BARTHOLOMAEUS WN, FIMMEL PJ, KEAST D AND STANLEY NF. (1980). Biologic and immunologic studies on a murine model of regional lymph node metastasis. J. Natl Cancer Inst. 64, 1363-1369.
13. GORELIK E. (1983). Resistance of tumor-bearing mice to a second tumor challenge. Cancer Res., 43, 138-145.
14. GORELIK E, SEGAL S AND FELDMAN M. (1981). On the mechanism of tumor 'concomitant immunity'. Int. J. Cancer, 27, 847-856.
15. HOWELL SB, DEAN JH AND LAW LW. (1975). Defects in cell-mediated immunity during growth of a syngeneic simian virus-induced tumor. Int. J. Cancer, 15, 152-169.
16. KEARNEY R AND NELSON DS. (1973). Concomitant immunity to syngeneic methylcholanthrene-induced tumours in mice. Occurrence and specificity of concomitant immunity. Aust. J. Exp. Biol. Med. Sci., 51, 723-735.
17. KESKI-OJA J, POSTLETHWAITE AE AND MOSES HL. (1988). Transforming growth factors in the regulation of malignant cell growth and invasion. Cancer Invest., 6, 704-724.
18. KLEIN S, COLOMBO LL, STILLITANI-D'ELÍA I AND BONAPARTE YP. (1980). Diferente inmunogenicidad de dos tumores de mama murinos con distinta capacidad metastásica en pulmón. Medicina (Buenos Aires), 40, 826-827.
19. KORDON E, LANARI C, MOLINOLO AA, ELIZALDE PV, CHARREAU EH AND PASQUALINI CD. (1991). Estrogen inhibitor of MPA-induced mouse mammary tumor transplants. Int. J. Cancer, 49, 900-905.
20. LEVESON SH, HOWELL JH, PAOLINI NS, TAN MH, HOLYOKE ED AND GOLDROSEN MH. (1979). Correlations between the leukocyte adherence inhibition microassay and in vivo tests of transplantation resistance. Cancer Res., 39, 582-586.
21. LOWRY OH, ROSEBROUGH HF, FARR ML AND RANDALL RF. (1951). Protein measurement with the Folin phenol reagent. J. Biol. Chem., 143, 265-275.
22. MEISS RP, BONFIL RD, RUGGIERO RA AND PASQUALINI CD. (1986). Histologic aspects of concomitant resistance induced by non-immunogenic murine tumors. J. Natl Cancer Inst., 76, 1163-1175.
23. NOMI S, NAITO K, KAHAN BD AND PELLIS NR. (1986). Effects of concomitant and sinecomitant immunity on postsurgical metastasis in mice. Cancer Res., 46, 6111-6115.
24. NORTH RJ. (1984). The murine antitumor immune response and its therapeutic manipulation. Adv. Immunology, 35, 89-155.
25. O'REILLY MS, HOLMGREN L, SHING Y, CHEN C, ROSENTHAL RA, MOSES M, LANE WS, CAO Y, SAGE EH AND FOLKMAN J. (1994). Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79, 315-328.
26. PASQUALINI CD AND COLMERAUER MEM. (1976). Immunological enhancement of a murine allogeneic lymphoma. Medicina (Buenos Aires), 36, 189-192.
27. PAZOS P, LANARI C, MEISS RP, CHARREAU EH AND PASQUALINI CD. (1992). Mammary carcinogenesis induced by N-methyl-N-nitrosourea (MNU) and medroxyprogesterone acetate (MPA) in BALB/c mice. Breast Cancer Res. Treatment, 20, 133-138.
28. PREHN RT. (1993). Two competing influences that may explain concomitant tumor resistance. Cancer Res., 53, 3266-3269.
29. RAO VS AND BONAVIDA B. (1976). Specific enhancement of tumor growth and depression of cell-mediated immunity following sensitization to soluble tumor antigens. Cancer Res., 36, 1384-1391.
30. RAO VS, BONAVIDA B, ZIGHELBOIM J AND FAHEY JL. (1974). Preferential induction of serum blocking activity and enhancement of skin allograft by soluble alloantigen. Transplantation, 17, 568-575.
31. RUGGIERO RA, BUSTUOABAD OD, BONFIL RD, MEISS RP AND PASQUALINI CD. (1985). 'Concomitant immunity' in murine tumours of non-detectable immunogenicity. Br. J. Cancer, 51, 37-48.
32. RUGGIERO RA, BUSTUOABAD OD, CRAMER P, BONFIL RD & PASQUALINI CD. (1990). Correlation between seric antitumor activity and concomitant resistance in mice bearing non-immunogenic tumors. Cancer Res., 50, 7159-7165.
33. TRINCHERI G AND PERUSSIA B. (1985). Immune interferon: a pleiotropic lymphokine with multiple effects. Immunol. Today, 6, 131-136.
34. TUTTLE RL, KNICK VC, STOPFORD CR AND WOLBERG G. (1983). In vivo and in vitro antitumor activity expressed by cells of concomitantly immune mice. Cancer Res., 43, 2600-2605.
35. VAAGE J. (1973). Influence of tumor antigen on maintenance versus depression of tumor-specific immunity. Cancer Res., 33, 493-503.
36. VAAGE J. (1977). Host serum factors versus tumor factors in immune resistance to metastases. In Cancer Invasion and Metastasis. Biologic Mechanisms and Therapy, Day SB Myers W, Stansly P, Garattini S AND Lewis M (eds) pp. 305-318. Raven Press: New York.
37. WINN HJ. (1961). Immune mechanisms in Homotransplantation II. Quantitative assay of the immunological activity of lymphoid cells stimulated by tumour homograft. J. Immunol., 86, 228-239.
38. WOGLOM WH. (1929). Immunity to transplantable tumours. Cancer Rev., 4, 129-209.
39. ZAHALKA MA, OKON E AND NAOR D. (1993). Blocking lymphoma invasiveness with a monoclonal antibody directed against the beta-chain of the leukocyte adhesion molecule (CD18). J. Immunol., 150, 4466-4477.